Drug Watch

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Check out the pipeline updates from April!

A groundbreaking study explores innovative neuroassessment technology to enhance understanding and treatment of borderline personality disorder symptoms.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.